English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In a recent editorial, Dr Van Poznak addresses the important issue of managing bone health in breast cancer patients receiving adjuvant treatment with an aromatase inhibitor [1]. Based on the published results of three clinical trials using risedronate [2,3] or ibandronate [4], it is concluded that oral bisphosphonates may be considered a supportive therapy to treat or prevent osteoporosis in breast cancer patients receiving aromatase inhibitor adjuvant treatment. We would like to comment on the results of those trials summarised in Table 1 of the editorial [1], focusing on patients with normal bone mineral density (BMD) or mild osteopaenia before starting treatment.

Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important